JP2010539508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539508A5 JP2010539508A5 JP2010525420A JP2010525420A JP2010539508A5 JP 2010539508 A5 JP2010539508 A5 JP 2010539508A5 JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010539508 A5 JP2010539508 A5 JP 2010539508A5
- Authority
- JP
- Japan
- Prior art keywords
- ccr4
- pamphlet
- tumor
- activity
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 43
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 20
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 16
- 230000000694 effects Effects 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 11
- 210000004369 blood Anatomy 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 7
- 230000004071 biological effect Effects 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000011394 anticancer treatment Methods 0.000 claims 5
- 230000002489 hematologic effect Effects 0.000 claims 4
- 210000000601 blood cell Anatomy 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 229940126669 CCR4 antagonist Drugs 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- WYVBISCFCHREDA-UHFFFAOYSA-N n-cycloheptyl-6,7-dimethoxy-2-(4-piperidin-1-ylpiperidin-1-yl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N2CCC(CC2)N2CCCCC2)=NC=1NC1CCCCCC1 WYVBISCFCHREDA-UHFFFAOYSA-N 0.000 claims 2
- 230000009257 reactivity Effects 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 102000004498 CCR4 Receptors Human genes 0.000 claims 1
- 108010017317 CCR4 Receptors Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 210000004882 non-tumor cell Anatomy 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0718167A GB0718167D0 (en) | 2007-09-18 | 2007-09-18 | Cancer marker and therapeutic target |
| GB0718167.0 | 2007-09-18 | ||
| PCT/GB2008/003160 WO2009037454A2 (en) | 2007-09-18 | 2008-09-18 | Cancer marker and therapeutic target |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015131752A Division JP6234967B2 (ja) | 2007-09-18 | 2015-06-30 | 癌マーカーおよび治療ターゲット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539508A JP2010539508A (ja) | 2010-12-16 |
| JP2010539508A5 true JP2010539508A5 (enExample) | 2012-10-04 |
| JP5774309B2 JP5774309B2 (ja) | 2015-09-09 |
Family
ID=38670078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525420A Expired - Fee Related JP5774309B2 (ja) | 2007-09-18 | 2008-09-18 | 癌マーカーおよび治療ターゲット |
| JP2015131752A Expired - Fee Related JP6234967B2 (ja) | 2007-09-18 | 2015-06-30 | 癌マーカーおよび治療ターゲット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015131752A Expired - Fee Related JP6234967B2 (ja) | 2007-09-18 | 2015-06-30 | 癌マーカーおよび治療ターゲット |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9134293B2 (enExample) |
| EP (3) | EP2533047B1 (enExample) |
| JP (2) | JP5774309B2 (enExample) |
| AU (1) | AU2008300413B2 (enExample) |
| CA (1) | CA2699702C (enExample) |
| DK (3) | DK2533047T3 (enExample) |
| ES (3) | ES2588507T3 (enExample) |
| GB (1) | GB0718167D0 (enExample) |
| PL (3) | PL2176664T3 (enExample) |
| RU (2) | RU2529797C2 (enExample) |
| WO (1) | WO2009037454A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0623815Y2 (ja) | 1988-10-06 | 1994-06-22 | 株式会社大金製作所 | エア回転継手のシール装置 |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| US9229004B2 (en) | 2008-09-26 | 2016-01-05 | The General Hospital Corporation | Methods for detecting and treating cancer |
| US11029313B2 (en) | 2008-09-26 | 2021-06-08 | The General Hospital Corporation | Method of treating cervical neoplasia in patients infected with human papilloma virus |
| GB0909906D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| WO2011157678A1 (en) * | 2010-06-14 | 2011-12-22 | Qiagen Gmbh | Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
| GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
| HK1212389A1 (en) | 2011-10-24 | 2016-06-10 | Signalchem Lifesciences Corporation | Carbonic anhydrase ix-related markers and use thereof |
| WO2013082490A1 (en) | 2011-12-01 | 2013-06-06 | Chemocentryx, Inc. | Substituted anilines as ccr(4) antagonists |
| GB2512857A (en) * | 2013-04-09 | 2014-10-15 | Cancer Res Technology | Cancer biomarker |
| WO2015069865A1 (en) * | 2013-11-06 | 2015-05-14 | Janssen Biotech, Inc. | Anti-ccl17 antibodies |
| WO2015184099A1 (en) | 2014-05-28 | 2015-12-03 | 4-Antibody Ag | Anti-gitr antibodies and methods of use thereof |
| SG11201702053TA (en) * | 2014-10-01 | 2017-04-27 | Sphingotec Gmbh | Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject |
| CN107624071A (zh) * | 2015-04-17 | 2018-01-23 | 诺福泰克公司 | 肺癌治疗方法 |
| EP3329244B1 (en) | 2015-07-30 | 2022-10-05 | Qiagen GmbH | Method of preparing a frozen biological sample |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| EP3626269A4 (en) | 2017-05-19 | 2021-03-03 | Shingo Maeda | METHOD FOR INFILTRATION OF REGULATORY T-CELLS USING CCR4 INHIBITION AND METHOD FOR TREATMENT OF NEOPLASTIC DISEASES IN DOGS |
| EP3843734A4 (en) | 2018-08-29 | 2022-05-25 | ChemoCentryx, Inc. | COMBINATION THERAPY USING C-CHEMOCINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| WO1994021814A1 (en) * | 1993-03-19 | 1994-09-29 | The Johns Hopkins University | Antibodies and assays for determining mutations in the apc gene |
| GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
| US6498015B1 (en) | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US6245332B1 (en) | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
| US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| AU3607301A (en) | 2000-03-03 | 2001-09-12 | Kyowa Hakko Kogyo Kk | Gene recombinant antibody and its fragment |
| WO2002030357A2 (en) | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
| US20020173524A1 (en) | 2000-10-11 | 2002-11-21 | Tularik Inc. | Modulation of CCR4 function |
| CA2423020C (en) | 2000-10-18 | 2009-01-20 | Schering Aktiengesellschaft | Use of antiprogestins for the induction of apoptosis in a cell |
| JP2004535157A (ja) * | 2001-02-28 | 2004-11-25 | プロテイン デザイン ラブス， インコーポレイテッド | ケモカイン受容体と疾患 |
| WO2002094264A1 (en) | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
| JP2005509408A (ja) | 2001-08-10 | 2005-04-14 | トピジェン・ファルマスーティック・インコーポレーテッド | 細胞ウイルス受容体およびその使用方法 |
| BRPI0212266B8 (pt) | 2001-08-31 | 2021-05-25 | Kyowa Hakko Kirin Co Ltd | anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| AU2003291549A1 (en) | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| EP1592708A2 (en) * | 2003-02-14 | 2005-11-09 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| SE0301650D0 (sv) | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
| SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| US7732442B2 (en) | 2003-09-05 | 2010-06-08 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
| EP1688436A4 (en) * | 2003-10-08 | 2009-12-02 | Kyowa Hakko Kirin Co Ltd | ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY |
| ATE486611T1 (de) | 2003-12-04 | 2010-11-15 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| JP2007217282A (ja) | 2004-03-04 | 2007-08-30 | Astellas Pharma Inc | 置換ピリミジン誘導体 |
| WO2005106471A2 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4) |
| JP2007269629A (ja) | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | キナゾリン誘導体 |
| RU2296328C1 (ru) * | 2005-09-21 | 2007-03-27 | Общество с ограниченной ответственностью "ГЕН" | Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| EP2365080B1 (en) | 2006-02-14 | 2016-04-13 | NOXXON Pharma AG | MCP-1 binding nucleic acids |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
-
2007
- 2007-09-18 GB GB0718167A patent/GB0718167D0/en not_active Ceased
-
2008
- 2008-09-18 PL PL08806315T patent/PL2176664T3/pl unknown
- 2008-09-18 EP EP12182790.1A patent/EP2533047B1/en not_active Not-in-force
- 2008-09-18 CA CA2699702A patent/CA2699702C/en not_active Expired - Fee Related
- 2008-09-18 US US12/679,002 patent/US9134293B2/en not_active Expired - Fee Related
- 2008-09-18 JP JP2010525420A patent/JP5774309B2/ja not_active Expired - Fee Related
- 2008-09-18 DK DK12182790.1T patent/DK2533047T3/en active
- 2008-09-18 ES ES12182790.1T patent/ES2588507T3/es active Active
- 2008-09-18 PL PL12183760T patent/PL2535716T3/pl unknown
- 2008-09-18 EP EP08806315.1A patent/EP2176664B1/en not_active Not-in-force
- 2008-09-18 DK DK12183760.3T patent/DK2535716T3/en active
- 2008-09-18 PL PL12182790.1T patent/PL2533047T3/pl unknown
- 2008-09-18 EP EP12183760.3A patent/EP2535716B1/en not_active Not-in-force
- 2008-09-18 DK DK08806315.1T patent/DK2176664T3/da active
- 2008-09-18 RU RU2010123921/15A patent/RU2529797C2/ru not_active IP Right Cessation
- 2008-09-18 WO PCT/GB2008/003160 patent/WO2009037454A2/en not_active Ceased
- 2008-09-18 AU AU2008300413A patent/AU2008300413B2/en not_active Ceased
- 2008-09-18 ES ES08806315.1T patent/ES2443541T3/es active Active
- 2008-09-18 ES ES12183760.3T patent/ES2612690T3/es active Active
-
2014
- 2014-07-14 RU RU2014128513A patent/RU2014128513A/ru not_active Application Discontinuation
-
2015
- 2015-06-30 JP JP2015131752A patent/JP6234967B2/ja not_active Expired - Fee Related
- 2015-08-11 US US14/823,755 patent/US10261099B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539508A5 (enExample) | ||
| RU2010123921A (ru) | Раковый маркер и терапевтическая мишень | |
| Prat et al. | Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay | |
| Blackhall et al. | Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer | |
| Leslie et al. | A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study | |
| JP2012526544A5 (enExample) | ||
| Tanaka et al. | Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma | |
| JP2009539097A (ja) | 循環腫瘍細胞アッセイ | |
| JP2012085556A (ja) | 乳がんの診断方法 | |
| Han et al. | Expression of PTEN and mTOR in pancreatic neuroendocrine tumors | |
| JP6983221B2 (ja) | 大腸癌の併用検査 | |
| JP2009511524A (ja) | ケモカイン発現のｅｇｆｒ依存調節ならびに腫瘍とその副作用の治療及び診断に与えるケモカイン発現調節の影響 | |
| Hou et al. | Detecting ALK-rearrangement of CTC enriched by nanovelcro chip in advanced NSCLC patients | |
| Liu et al. | Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer | |
| Wang et al. | Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma | |
| Sandri et al. | Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma | |
| Ikuta et al. | The current management of clear cell sarcoma | |
| Obata et al. | Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer | |
| JP2012526543A5 (enExample) | ||
| CN116559462A (zh) | 用于肿瘤患者预后的生物标志物组及其用途 | |
| JP2012085554A (ja) | 乳がんのサブタイプの判別方法 | |
| JP2007523640A5 (enExample) | ||
| He et al. | Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma | |
| JP6466911B2 (ja) | Ｃｃｌ２２及びｃｃｌ１７癌生物マーカー | |
| JP2008535491A5 (enExample) |